Search Results - michael+xing

10 Results

Sort By:

A Molecular Mechanism for the Activation of Mutant TERT by the BRAF V600E/MAP Kinase Pathway

Unmet NeedThe oncogenic duet of BRAF V600E and TERT promoter mutations occurs in approximately 7-8% of papillary thyroid cancer (PTC) cases and 20-50% of melanoma cases. These percentages also correspond to the proportion of cases with the poorest clinical and pathological outcomes. When mutations in either of these oncogenes alone are present, only...

Published: 6/27/2025 | Inventor(s): Michael Xing, Rengyun Liu

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Clinical and Disease Specializations > Oncology > Melanoma

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer with Highest Recurrence

BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer with Highest RecurrenceJHU REF: C12971Invention Novelty: This invention discloses the coexistence of BRAF V600E and TERT C228T mutations as novel molecular marker that defines the most aggressive subgroup of certain cancers (papillary thyroid cancer...

Published: 6/26/2025 | Inventor(s): Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics, Thyroid Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Endocrinology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

TERT Promoter Mutations in Thyroid Cancer

Novel Thyroid Cancer Diagnostic and Prognostic BiomarkerJHU REF: C12422Invention novelty: This technology detects somatic mutations that occur at high frequency in papillary, follicular and anaplastic thyroid cancers.Value Proposition:Papillary and follicular thyroid carcinomas account for 80-90% of thyroid cancers, and anaplastic thyroid cancer accounts...

Published: 6/26/2025 | Inventor(s): Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

RASAL1 is a Major Tumor Suppressor Gene in Thyroid Cancer

Novel Molecular Diagnostics for Thyroid CancerJHU REF: C12597Invention novelty: This invention has identified a novel tumor suppressor gene, RASAL1 in thyroid cancers. Genetic mutations and epigenetic alterations of the RASAL1 gene can be used for the diagnosis of thyroid cancers.Value Proposition:Papillary and follicular thyroid carcinomas account...

Published: 6/26/2025 | Inventor(s): Dingxie Liu, Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics, Thyroid Cancer

JHU REF: C12704 - NOVEL STRATEGIES TO OVERCOME MELANOMA DRUG RESISTANCE

Invention novelty: Novel methods for predicting melanoma resistance to BRAF/MEK inhibitors and for treating melanoma cancer patients.Value Proposition:An estimated 76,690 new cases of invasive melanoma will be diagnosed in the US in 2013 and an estimated 9,480 people will die of melanoma in 2013. Although BRAF and MEK inhibitors have proven clinical...

Published: 6/26/2025 | Inventor(s): Dingxie Liu, Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Melanoma, Pharmakodynamic Biomarker, Skin Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Melanoma, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

A Novel Target for Anti-cancer Drug Development

C11563: A Novel Target for Anti-cancer Drug DevelopmentNovelty: This technology identifies novel oncogenic mutations in a gene that contribute to cancer development suggesting new opportunities for therapeutic management using inhibitors of this gene.Value Proposition: The researchers have identified unreported changes in a genes amino acid sequence...

Published: 6/26/2025 | Inventor(s): Avaniyapuram Murugan, Michael Xing

Keywords(s): Biomarker, Cancers, Disease Indication, Gene Therapy, Mechanism-of-action Biomarker, Single, Target, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities

Analyses of GNAQ, MMP8, AKT3, EGFR and PIK3R1 Mutations in Thyroid Cancers

C11181: Gene Mutations as Diagnostic Targets in CancerNovelty: This discovery identifies the novel oncogenic mutations in various thyroid cancers that can be effective diagnostic markers for thyroid and other human cancers.Value Proposition: Cancer is the second most common cause of death in the industrialized world. Blood tests, imaging and biopsies...

Published: 6/26/2025 | Inventor(s): Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Thyroid Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Endocrinology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

IQGAP1 Plays an Important Role in the Invasiveness and Aggressiveness of Thyroid Cancer

C11026: Diagnostic and Prognostic Biomarker for Thyroid CancerNovelty: A copy number mutation for gene IQGAP1 is described that can be used in prognostic and diagnostic tests for cancer, specifically thyroid cancer.Value Proposition: Over the last 40 years the incidence of thyroid cancer has nearly doubled. A highly specific protein mutation will allow...

Published: 6/26/2025 | Inventor(s): Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Prognostic Biomarker, Thyroid Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Endocrinology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

C10292: Combination Therapy for Thyroid Cancer and Melanoma

Novelty: Application of radioiodine therapy for the treatment of undifferentiated thyroid cancer and melanoma facilitated by induction of iodide-handling genes via dual suppression of PI3K/Akt and MAP kinase pathwaysValue Proposition: Thyroid cancer is typically treated by radioiodine therapy, which exploits the unique capability of thyroid cells to...

Published: 6/26/2025 | Inventor(s): Michael Xing

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics, Thyroid Cancer

BRAF Mutation Occurs in a Majority of Papillary Thyroid Carcinoma

Unmet Need:Papillary thyroid cancer (PTC) is the most common thyroid cancer, accounting for about 80% of thyroid malignancies. Although PTC is usually indolent and curable with surgical thyroidectomy followed by radioiodine treatment, many patients do have recurrence and some become incurable and will die from the disease. Consequently, it is important...

Published: 6/26/2025 | Inventor(s): David Sidransky, Michael Xing, Yoram Cohen

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Therapeutic Matter, Therapeutics, Thyroid Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Endocrinology, Clinical and Disease Specializations > Oncology > Thyroid Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities